Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Kjetil Søreide

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7594-4354; OpenAlex author ID A5023509995. Sources: OpenAlex.

Their work

Papers
30 (first author 6, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 6 papers · 2023: 4 papers · 2024: 5 papers · 2025: 5 papers · 2026: 3 papers

Papers 30

  1. Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies. Co-author DOI 10.1002/wjs.70347↗
  2. Outcomes after surgery for locally advanced pancreatic cancer compared to borderline and upfront resectable pancreatic cancer. Co-author DOI 10.21037/hbsn-2025-aw-868↗
  3. Malpractice claims for pancreatic cancer in Norway: claim-rates, injury domains, claim outcomes and indemnity compensation. Last author DOI 10.2340/ao.v65.45500↗
  4. Patient-derived organoids from pancreatic cancer after pancreatectomy: Feasibility and organoid take rate in treatment-naïve periampullary tumors. Last author DOI 10.1016/j.pan.2024.12.018↗
  5. Patient-derived organoids from EUS-guided biopsies in pancreatic cancer: moving the needle for precision medicine. Co-author DOI 10.1016/j.pan.2025.10.007↗
  6. A decade of patient-derived organoids in pancreatic cancer: points in translation. Last author DOI 10.1080/00365521.2025.2555701↗
  7. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  8. Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study. Co-author DOI 10.1245/s10434-024-16291-9↗
  9. Comparing in vitro cytotoxic drug sensitivity in colon and pancreatic cancer using 2D and 3D cell models: Contrasting viability and growth inhibition in clinic… Co-author DOI 10.1002/cam4.7318↗
  10. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. First author DOI 10.1080/00365521.2024.2378948↗
  11. Surgery for oligometastatic pancreatic cancer: next frontier? First author DOI 10.1093/bjs/znad419↗
  12. ASO Author Reflections: Response to Chemotherapy Differs between Precursor Epithelial Subtypes of Pancreatic Adenocarcinoma Arising from Intraductal Papillary … First author DOI 10.1245/s10434-024-15784-x↗
  13. Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials. Co-author DOI 10.1245/s10434-024-16134-7↗
  14. Pancreatic cancer. Co-author DOI 10.1016/j.ejso.2023.01.001↗
  15. Call for better response evaluation after neoadjuvant therapy in pancreatic cancer. First author DOI 10.1093/bjs/znac452↗
  16. Early Diagnosis of Pancreatic Cancer: Clinical Premonitions, Timely Precursor Detection and Increased Curative-Intent Surgery. Co-author DOI 10.1177/10732748231154711↗
  17. Is there a survival benefit of a robotic approach to pancreatoduodenectomy for pancreatic cancer? Last author DOI 10.21037/hbsn-22-500↗
  18. Accuracy of Lymph Node Staging in Pancreatic Cancer after Neoadjuvant Therapy. First author DOI 10.1007/s00268-021-06431-7↗
  19. Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.02.001↗
  20. Fluid-sensitive migration mechanisms predict association between metastasis and high interstitial fluid pressure in pancreatic cancer. Co-author DOI 10.1016/j.jbiomech.2022.111362↗
  21. Metabolic flux analysis of 3D spheroids reveals significant differences in glucose metabolism from matched 2D cultures of colorectal cancer and pancreatic duct… Co-author DOI 10.1186/s40170-022-00285-w↗
  22. The prognostic relevance of examined lymph nodes for accurate staging of resected pancreatic adenocarcinoma. Last author DOI 10.21037/hbsn-2022-14↗
  23. Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14030546↗
  24. Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?). Co-author DOI 10.1007/s40487-020-00136-y↗
  25. Heterogeneity in neoadjuvant therapy for localized pancreatic cancer: a persisting radiant autonomy. Co-author DOI 10.21037/hbsn-2020-9↗
  26. Regionalization of Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2020.0850↗
  27. Refined TNM-staging for pancreatic adenocarcinoma - Real progress or much ado about nothing? Last author DOI 10.1016/j.ejso.2020.02.014↗
  28. Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis. Co-author DOI 10.1089/pancan.2019.0014↗
  29. Trials and tribulations of neoadjuvant therapy in pancreatic cancer. First author DOI 10.1002/bjs.11003↗
  30. Sweet Predictions Speak Volumes for Early Detection of Pancreatic Cancer Co-author DOI 10.1053/j.gastro.2018.06.054↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcus T. T. Roalsø · 7 shared papers, 2020–2025 · strength 1.79
  2. Claudia Zaharia · 5 shared papers, 2022–2025 · strength 1.48
  3. Patrik Larsson · 3 shared papers, 2024–2025 · strength 1.10
  4. Sanjay Pandanaboyana · 3 shared papers, 2024–2026 · strength 1.01
  5. Hanne Røland Hagland · 3 shared papers, 2022–2025 · strength 0.75
  6. Nigel Balfour Jamieson · 1 shared paper, 2026 · strength 0.63
  7. Tia Tidwell · 2 shared papers, 2022–2024 · strength 0.48
  8. Ernesto Sparrelid · 2 shared papers, 2024–2025 · strength 0.44
  9. Daniel Öhlund · 1 shared paper, 2025 · strength 0.42
  10. Annbjørg Hegelstad Søreide · 1 shared paper, 2026 · strength 0.39
  11. Karin Hestnes Edland · 1 shared paper, 2026 · strength 0.39
  12. Jan Rune Aunan · 2 shared papers, 2020 · strength 0.38
  13. James E. Lucocq · 1 shared paper, 2024 · strength 0.36
  14. Sheraz Yaqub · 1 shared paper, 2023 · strength 0.31
  15. Dyre Berg Kleive · 1 shared paper, 2023 · strength 0.31
  16. Jaswinder Singh Samra · 1 shared paper, 2026 · strength 0.29
  17. Keith John Roberts · 1 shared paper, 2026 · strength 0.29
  18. Vivek Peddakota · 1 shared paper, 2026 · strength 0.29
  19. Anubhav Mittal · 1 shared paper, 2026 · strength 0.29
  20. Poya Ghorbani · 1 shared paper, 2025 · strength 0.28
  21. Stefan Stättner · 1 shared paper, 2023 · strength 0.24
  22. Elena B. Rangelova · 1 shared paper, 2023 · strength 0.24
  23. Jacob Ghotbi · 1 shared paper, 2023 · strength 0.24
  24. Einar K. Rofstad · 1 shared paper, 2022 · strength 0.22
  25. Steinar Evje · 1 shared paper, 2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.